IL218302A - Use of compounds for the preparation of drugs for the treatment of acute voice trauma - Google Patents

Use of compounds for the preparation of drugs for the treatment of acute voice trauma

Info

Publication number
IL218302A
IL218302A IL218302A IL21830212A IL218302A IL 218302 A IL218302 A IL 218302A IL 218302 A IL218302 A IL 218302A IL 21830212 A IL21830212 A IL 21830212A IL 218302 A IL218302 A IL 218302A
Authority
IL
Israel
Prior art keywords
medicaments
compounds
preparation
treating acute
acoustic trauma
Prior art date
Application number
IL218302A
Other languages
English (en)
Hebrew (he)
Other versions
IL218302A0 (en
Inventor
Dana Kopke Richard
A Floyd Robert
Original Assignee
Oklahoma Med Res Found
Hough Ear Inst
Dana Kopke Richard
A Floyd Robert
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oklahoma Med Res Found, Hough Ear Inst, Dana Kopke Richard, A Floyd Robert filed Critical Oklahoma Med Res Found
Publication of IL218302A0 publication Critical patent/IL218302A0/en
Publication of IL218302A publication Critical patent/IL218302A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Endoscopes (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IL218302A 2009-08-24 2012-02-23 Use of compounds for the preparation of drugs for the treatment of acute voice trauma IL218302A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27411809P 2009-08-24 2009-08-24
PCT/US2010/046420 WO2011028503A1 (en) 2009-08-24 2010-08-24 Methods for treating acute acoustic trauma

Publications (2)

Publication Number Publication Date
IL218302A0 IL218302A0 (en) 2012-04-30
IL218302A true IL218302A (en) 2017-02-28

Family

ID=43649578

Family Applications (1)

Application Number Title Priority Date Filing Date
IL218302A IL218302A (en) 2009-08-24 2012-02-23 Use of compounds for the preparation of drugs for the treatment of acute voice trauma

Country Status (8)

Country Link
US (2) US10555915B2 (https=)
EP (1) EP2470015B1 (https=)
JP (2) JP5762414B2 (https=)
AU (1) AU2010289838C1 (https=)
CA (1) CA2772097C (https=)
ES (1) ES2563777T3 (https=)
IL (1) IL218302A (https=)
WO (1) WO2011028503A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10751385B2 (en) 2015-02-20 2020-08-25 Institut Pasteur Prevention and/or treatment of hearing loss or impairment
US20180256756A1 (en) * 2015-09-18 2018-09-13 Oklahoma Medical Research Foundation Method of transporting an agent across blood-brain, blood-cochlear or blood-cerebrospinal fluid barrier
TWI642431B (zh) * 2016-10-28 2018-12-01 西德有機化學藥品股份有限公司 Ｎ－乙醯半胱胺酸用於治療突發性感覺神經性聽力損失的方法
CN110248650A (zh) * 2016-10-31 2019-09-17 霍夫耳科研究所 用于增强突触发生和神经突发生的方法
KR20190119046A (ko) * 2017-01-19 2019-10-21 오톨로직 파마슈틱스, 인크. N-아세틸시스테인의 제제 및 이의 용도
JP6999896B2 (ja) 2017-09-21 2022-01-19 学校法人慶應義塾 音響外傷難聴モデル動物の作製方法及びそれにより作製される音響外傷難聴モデル動物
US20210137861A1 (en) * 2018-05-03 2021-05-13 Hough Ear Institute Methods for reducing accumulated pathologic tau protein
AU2019339352B2 (en) * 2018-09-12 2025-05-22 Hough Ear Institute Methods for treating hearing loss incident to cochlear implant surgery
US11857551B1 (en) 2020-07-10 2024-01-02 Ting Therapeutics Llc Methods for the prevention and treatment of hearing loss
EP4309655A1 (en) * 2022-07-22 2024-01-24 Consejo Superior de Investigaciones Científicas (CSIC) Quinolylnitrone derivatives for use in the prevention and/or treatment of hearing loss

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5488145A (en) * 1993-12-23 1996-01-30 Oklahoma Medical Research Foundation 2,4-disulfonyl phenyl butyl nitrone, its salts, and their use as pharmaceutical free radical traps
US6177434B1 (en) * 1997-12-16 2001-01-23 The United States Of America As Represented By The Secretary Of The Navy Prevention or reversal of sensorineural hearing loss (SNHL) through biologic mechanisms
US6649621B2 (en) * 1997-12-16 2003-11-18 The United States Of America As Represented By The Secretary Of The Navy Prevention or reversal of sensorineural hearing loss (SNHL) through biologic mechanisms
US6469049B1 (en) 2000-04-21 2002-10-22 The United States Of America As Represented By The Secretary Of The Army Method of treating, preventing or inhibiting central nervous system injuries and diseases
SE0001916D0 (sv) 2000-05-23 2000-05-23 Astrazeneca Ab Novel formulation
WO2004096256A1 (en) 2001-01-23 2004-11-11 The United States Of America, As Represented By The Secretary Of The Navy Methods for preventing and treating loss of balance function due to oxidative stress
US7700111B2 (en) * 2002-01-17 2010-04-20 The Regents Of The University Of Michigan Auditory nerve protection and re-growth
WO2005016243A2 (en) 2003-06-09 2005-02-24 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and an antioxidant agent for the treatment of central nervous system disorders
US20050182060A1 (en) 2004-02-13 2005-08-18 Kelly Michael G. 2-Substituted and 4-substituted aryl nitrone compounds
WO2007119578A1 (ja) 2006-03-29 2007-10-25 Kaneka Corporation 神経系細胞機能改善剤
AU2007277193B2 (en) * 2006-07-25 2013-06-13 Hough Ear Institute Methods for treating acute acoustic trauma
UA97486C2 (ru) 2006-08-29 2012-02-27 Дженентек, Инк. Применение тенектеплазы для лечения острого ишемического инсульта
US20100234402A1 (en) * 2007-05-31 2010-09-16 Gideon Dreyfuss Methods and compositions for treating spinal muscular atrophy
KR20130097813A (ko) * 2008-04-21 2013-09-03 오토노미, 인코포레이티드 귀 질환 및 병태를 치료하기 위한 귀 조제물
US20140302322A1 (en) 2011-09-06 2014-10-09 Ricardo Prada Silvy Single wall carbon nanotube purification process and improved single wall carbon nanotubes

Also Published As

Publication number Publication date
AU2010289838A1 (en) 2012-04-19
AU2010289838B2 (en) 2013-11-07
WO2011028503A1 (en) 2011-03-10
US10555915B2 (en) 2020-02-11
JP2013502461A (ja) 2013-01-24
JP5762414B2 (ja) 2015-08-12
EP2470015B1 (en) 2016-01-13
CA2772097C (en) 2019-04-30
CA2772097A1 (en) 2011-03-10
US20120172435A1 (en) 2012-07-05
EP2470015A4 (en) 2013-01-09
IL218302A0 (en) 2012-04-30
AU2010289838C1 (en) 2014-03-06
US20170224635A1 (en) 2017-08-10
ES2563777T3 (es) 2016-03-16
JP6038233B2 (ja) 2016-12-07
JP2015172071A (ja) 2015-10-01
EP2470015A1 (en) 2012-07-04

Similar Documents

Publication Publication Date Title
IL218302A (en) Use of compounds for the preparation of drugs for the treatment of acute voice trauma
HUE047994T2 (hu) Bardoxolon-metil elhízás kezelésére
IL203051A (en) Use of alpha-ketoglutarate for drug preparation
IL222890A0 (en) Medicaments for the treatment of il-1beta related conditions
ZA201101836B (en) Process for the preparation of rufinamide
SI2387566T1 (sl) Postopek za pripravo rosuvastatina
IL213761A0 (en) Novel ortho-aminoamides for the treatment of cancer
GB0906159D0 (en) Drug combination for the treatment of proteostatic diseases
GB0715790D0 (en) Drug combination for the treatment of sialorrhoea
IL211189A0 (en) Compounds for the treatment of peripheral neuropathies
IL200032A0 (en) Medicament for the treatment of endometriosis
IL216491A0 (en) Combination therapy for the treatment of multiple myeloma
PL2285780T3 (pl) Sposoby i związki do wytwarzania normorfinanów
ZA201201740B (en) Process for the preparation of cathepsin s inhibitors
ZA200905300B (en) Medicament for the treatment of endometriosis
IL215854A0 (en) Pharmaceutical compositions for the treatment of nasal polyposis
EP2575926B8 (en) Apparatus for the treatment of the blood
PL2229943T3 (pl) Związek do zastosowania w leczeniu neuropatii obwodowych
HK1169987A (en) Compound suitable for the treatment of synucleopathies
IL215143A0 (en) Process for the preparation of alogliptin
AU2010901601A0 (en) Compound for the treatment of respiratory condition or disease
GB0920317D0 (en) Compounds for the treatment of neoplasia
GB0906202D0 (en) Compounds for the treatment of neoplasia
GB0908699D0 (en) Compounds for the treatment of neoplasia
GB0914476D0 (en) Compounds for the treatment of neoplasia

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed